

EGG PHARMA Holistic Formulary Act RX DENGUE & MALARIA CURE




Malaria kills an African child every 30 seconds, many of whom die because they are unable to reach medical help in time. A new sublingual spray could help cut deaths by helping children recover sufficiently to survive the journey to hospital

**Energime Green Group, Thailand, Ltd (EGG)
www.lazerhead.net
www.energime.com & www.originoil.com**

June 29th, 2015


Energime Green Group ~ Water & Waste Treatment is part of the EGG solution to prevent spread and breeding of Dengue & Malaria





A mosquito's vicious circle

Here's how mosquitoes spread diseases such as malaria:

- 1 Parasite injected by infected mosquito as it feeds on blood.
- 2 Parasite develops in body tissues.
- 3 Parasite infects other feeding mosquitoes.
- 4 Parasites live in salivary glands, waiting for next victim.



MSNBC / B




Dengue Disease in Brasil:

736,000 get Dengue in first 4 months of 2015

The Disease

What is malaria?




Malaria is a serious and sometimes fatal disease caused by a parasite that commonly infects a certain type of mosquito which feeds on humans. People who get malaria are typically very sick with high fevers, shaking chills, and flu-like illness. Four kinds of malaria parasites have long been known to infect humans: *Plasmodium falciparum*, *P. vivax*, *P. ovale*, and *P. malariae*.

Severe malaria is a medical emergency. The disease can progress quickly, leading to severe anaemia, respiratory distress and neurological symptoms including seizures and coma.

ACT RX Cures Dengue & Malaria in 2 days for \$35

Globally, the World Health Organization estimates that in 2010, 219 million clinical cases of malaria occurred, and 660,000 people died of malaria, most of them children in Africa. Because malaria causes so much illness and death, the disease is a great drain on many national economies. Since many countries with malaria are already among the poorer nations, the disease maintains a vicious cycle of disease and poverty.

In 2013, there were about 198 million malaria cases and an estimated 584 000 malaria deaths



ActRx is the newest proprietary, Patent-Pending ACT formulation designed by researchers from the United States and Asia for the treatment of Malaria, both severe and uncomplicated. The Humanitarian Foundation has discovered that the Treatment was also effective on many cases involving Dengue Fever and Dysentery.



India's Dengue Burden over 0.5 % of population at 5.8 mln cases/year!

(parasitemia in kids 6-59 mo is 44.9% in Guinea)

-  Malaria
-  Dengue Fever
-  West Nile Virus





TRAVEL SAFE 
Para'Kito™ is allowed
in cabin luggage.

Increased prevention and control measures have led to a reduction in malaria mortality rates by 47% globally since 2000 and by 54% in the WHO African Region.

People living in the poorest countries are the most vulnerable to malaria. In 2013, 90% of all malaria deaths occurred in the WHO African Region, mostly among children under 5 years of age.


ACT RX – 100% Effective Results



For those fortunate enough to reach a medical centre for specialist care, treatment is likely to take the form of quinine or artesunate via an intravenous drip. For obvious reasons, this form of therapy can only be provided by a trained medical professional in a hospital setting and is expensive for developing countries. As it stands, there is no effective alternative for treating children with severe malaria closer to home, but this may be about to change.

A sublingual (beneath the tongue) spray is for the treatment of adults & children with severe malaria. The fast-acting nature of this spray means that within 48 hours, children should have recovered to eat and take on fluids.

Sublingual spray Easy to administer at home without shots!



ACT RX 100% Effective Results

Saving Children's Lives



ANOTHER CHILD SAVED AND CURED FROM DENGUE FEVER

Twelve year old Mark Aaron Pinlac had been confined at Angeles Medical Center in Angeles City due to high fever, intense body pain, headaches and severe nose bleeding. He was diagnosed with Dengue hemorrhagic fever with his physician putting the boy on IV fluids and Paracetamol but the symptoms continued and his 62,000 platelet count continually dropped to a low of 38,000 and his nose continued to bleed.



Mark Aaron Pinlac

Fearing for his life, since they had heard of the many deaths from Dengue, the Pinlacs chose to have the new ActRx TriAct® treatment administered to their son. Within an hour of spraying the first portion of the treatment, a sublingual spray, young Mark regained his appetite. Then that afternoon, he informed his parents that the body pain and headache had lessened and the nose bleed had stopped, never to return. Within 48 hours of the full treatment, which included the administering of Berberine and Artesunate tablets, all the Dengue symptoms were gone. Mark's platelet count normalized within 72 hours, with his parents amazed at his rapid recovery... only after the ActRx TriAct® treatment


There were no adverse side effects and Mark quickly returned to being an energetic young boy, with his family agreeing that they believed the natural and innovative ActRx TriAct® treatment had saved Mark's life.

***Easy to use
and fast-acting
nature of ACT
RX is perfect
for home
administration
Dengue- virus
+ chikungunya
+ Yellow Fever
cure within 48
hours + cures
malaria 5 days
Affordable!***

Once approved for use outside of a hospital setting, the spray (which does not require refrigeration) can be applied by anyone with minimal training. Children should therefore be able to access the treatment locally.




The administration of drugs sublingually (beneath the tongue) is not a new concept. For example, sublingual nitroglycerin (a potent vasodilator) is commonly prescribed for the treatment of angina. In this scenario, the administration of the drug beneath the tongue offers significant advantages due to the speed of action. The blood vessels in the mouth are both plentiful and close to the surface, meaning the active ingredient is absorbed and can act on blood vessels throughout the body in a matter of minutes.




Scientists discover how Dengue Fever virus infects living cells

Sublingual Spray


Tri-i-Act Cures in 48 hours with 100% success



ActRx
Natural
Medicine



The ACTRX spray for childhood malaria contains artemether, an extremely effective antimalarial agent which is already commonly used in the treatment of 'uncomplicated' (non-severe) cases of the disease. Derived from artemisinin (which is itself isolated from a Chinese medicinal herb), artemether is generally used in tablet form combined with a second antimalarial agent






Sublingual Spray
Tri-i-Act Cures in 48
hours with 100%
success

ActRx
Natural
Medicine



Artemisinin and Its Derivatives
artemisinin combinations are superior In those areas where resistance to sulphonamide-pyrimethamine, chloroquine and amodiaquine is prevalent




Although highly active against all Plasmodium species, the short half-life of these drugs till Act Rx have always limited their use as a single agent, since a minimal treatment course of seven days is needed in order to cover at least 3 erythrocytic cycles of the parasite. However, their potent action and short half-lives reduces the risk of resistance development, and makes the drugs an ideal candidate for the use in combination ACT RX therapies.


Artemisinin and its derivatives are remarkably well tolerated, with very rare serious adverse effects. The only evidence of toxicity documented in large clinical trials to date has been a temporary depression in reticulocyte counts, which does not translate into anemia, acute (type 1)

ACTRX is 7x's More Effective! Artesunate, like chloroquine, is a 4-aminoquinoline, but it is effective against chloroquine resistant strains of *P. falciparum*, **with combined spray/pill regime!**


Scientists discover how.,



Between 1% – 5% of all people that contract dengue die without treatment.



Dengue Fever virus infects living cells





Dengue is the most common arthropod-borne viral (arboviral) illness in humans. It is transmitted by mosquitoes of the genus Aedes, which are widely distributed in subtropical and tropical areas of the world.

Persons who have previously been infected by one dengue serotype develop bleeding and endothelial leak upon infection with another dengue serotype. This syndrome is termed dengue hemorrhagic fever- with 26% mortality

To infect a cell, the dengue virus (counterclockwise, from upper left), binds to the cell membrane. The virus is then enveloped in the membrane, which coalesces around the virus, forming a pouch-like structure called an endosome. Deep inside the cell, the endosome membrane acquires a negative charge, which allows the virus to fuse with the endosomal membrane and release genetic material into the cell's interior.

The Positives

Artemether is rapidly metabolised by the liver and converted to the derivative dihydroartemisinin (DHA), which reaches its maximum concentration in the body around two to three hours after dosing. Both artemether itself and DHA have strong antimalarial properties, reducing the parasite biomass by about 10,000-fold per asexual life cycle (around two days). 48 hours





The Positives

The Positives



As in the case of nitroglycerin, sublingual application allows the drug to by-pass the digestive system. Not only does this increase the speed at which the drug can act, but absorption directly into the systemic blood circulation means that 'first-pass' metabolism by the liver is avoided entirely.


This increases artemether bioavailability up to threefold in the first instance, but up to 7-fold with repeated dosing compared to oral formulations.



Docosahexaenoic acid (DHA), is a systematic name. Docosa refers to the 22 carbon atoms in the chain and hexa refers to 6 double bonds.



"ACTRX TRIACT Prevents Tolerance"




Trials to date have taken place in hospitals, but it is envisaged that in the future the spray will be used locally at the child's family home. It is important to point out that children with severe malaria will still need to travel to hospital for further treatment, even after successful treatment with the spray. However, children who receive sublingual artemether will be in a far better state of health to travel and should therefore stand a significantly better chance of surviving.





DENGUE

And complications including Dengue Shock Syndrome



<i>Works for Dengue and Malaria without tolerance building up as in most monotherapies</i>	<i>Most of these are in tropical areas of the world, with the greatest risk occurring</i>	<i>transmitted by the bite of an Aedes mosquito infected with a dengue virus</i>	<i>characterized by high fever, damage to lymph and blood vessels, bleeding from the nose and gums,</i>	<i>enlargement of the <u>liver</u>, and failure of the circulatory system.</i> <i>The symptoms may progress to massive bleeding, shock, and death. This is called dengue shock</i>
WHO predicts 200 million cases of <u>dengue fever</u> occur worldwide. 584,000 die of Malaria also!	<i>drug may also prove to be an effective treatment for other viruses. With severe dengue there is a 26% mortality</i>	<i>serious problems can develop. These include dengue hemorrhagic fever, a rare complication</i>	In 2012 there were 22,000 deaths due to dengue.	




“ACTRX TRIACT THERAPY”



Dedicated to eradicate tropical vector-borne diseases utilizing alternative/natural medication and innovative delivery systems

“A Prospective, Multi-Center, Randomized Controlled Trial in the Efficacy and Safety of Artemether + Artesunate in Combination with Berberine in the Treatment of Dengue Patients” has been found to be complete in form and content based on the prescribed format used in our projects. Moreover, review of the protocol show that it is scientifically valid and sound to be carried in hospitals.” To further validate the efficacy of the treatment, the DOH, deemed it proper to implement the study thru a larger scale clinical trial which aims to treat 2,000 atients who are diagnosed with Dengue .”

Philippine Institute of Traditional and Alternative Health Care (PITAHC)



***Monotherapies
Vs.
Triact Therapies***



“Berberine + Arthemether”



East African Medical Journal entitled “*Treatment of chloroquine-resistant malaria using pyrimethamine in combination with berberine, tetracycline or cotrimoxazole,*” (Annex C) results showed that berberine has a greater clearing effect than the other treatment arms.


Since there is proof that berberine has anti-malarial properties, the researchers now aim to test whether berberine plus artemether, artesunate, and primaquine may be efficacious for the treatment of malaria.

**Berberine as
superior
Clearing Agent**

© iStockphoto / Thinkstock

Under the supervision and control of the DOH thru the auspices of PITAHC. Comparison of the two treatment arms showed a drastic improvement within 24 to 48 hours in the experimental study arm. There were no deaths and absolutely no safety issues.

**Monotherapies
Vs.
Triact Therapies**



"TRI-Act Combined Therapy Is Synergistic"

- It must be stressed that some of the components, Artemether + Artesunate, are already established as anti-malarial drug being used for many years. (except when combined with Quinine – the third component being used today in the treatment of malaria patients)***

•The approval by the Philippine FDA thru issuance of 4 separate permits dated June 7, 2012 and July 4, 2012 for all the components of the ActRx Research Treatment, allowing its entry into Philippine Jurisdiction "to be used only for clinical trials and should not find its way into the market". Along with a United States FDA and Department of Health and Human Services approval of protocol for clinical trials on human subjects using the ActRx Research Treatment for Dengue clearly establishes that it is safe and non-toxic.



The Protocols to be used in the research involving the same are in accordance with International Standards as evidenced by the approval of the US Department of Health and Human Services Institutional Review Board IRB No. IORG0006761-7. In the same vein due consideration for Health and Safety Issues have been thoroughly studied. Otherwise, The US Department of Health & Human Services and FDA would not have issued the 'go ahead' or approval of the protocol, to conduct testing on humans unless they were sufficiently convinced of the safety and non-toxicity of the products. It would be absurd to assume that the US government does not comply or meet International Standards. It is a well established fact that the United States Department of HHS and the Federal FDA is one of the world's most respected institutions. Its ethical standards and guidelines are one of the strictest worldwide.

"TRI-Act Combined Therapy Is Synergistic"

The components of the treatment of ACTrx namely, Artemisinin, and its derivatives Artesunate, Artemether are already being used and is considered as the primary choice in treating Malaria as espoused by the World Health Organization. While the other component of the treatment, Berberine, is a derivative of the Barbaru Root, which is considered as a traditional medicine or a dietary supplement over 2,000 years. To date, there have been no reported side effects and/or health risks in the consumption of it. In fact, in newer and experimental uses, it has shown to exert synergistic effects.

- ALL components or active ingredients of the treatment are herbal based. They are bi-products of plants and roots. (from the Artemesia Annua plant which contains ARTEMISININ in the FORM of ARTESUNATE. If you will check, both ARTEMETHER and ARTESUNATE, are registered drugs which have long been used all over the world and is SAFE FOR HUMAN USE.

UN estimates of the number of people at risk today: 2.5 billion people, rising to 5 or 6 billion people by 2085 (assuming climate change and population growth). The increase due to climate change alone would more than double the number at those at risk to an estimated 3.5 billion.

“Malaria Burden Estimation Maps of India”

credible diagnostic facilities and reporting system. In the south-east Asian Region of WHO, out of about 1.4 billion people living in 11 countries (land area 8,489,600 km², i.e. 6% of global area), 1.2 billion are exposed to the risk of malaria and most of whom live in India (Kondrachine 1992). However, the south-east Asia contributed only 2.5 million cases to the global burden of malaria. Of this, India alone contributed 76% of the total cases. Taking into account clinical episodes, it has now been estimated with the help of epidemiological models, geographical and demographic data that *P. falciparum* estimates






Fig. 3: Trends of malaria incidence in India from 1960 to 2005. Nearing eradication in 1960s (<100,000 cases) to resurgence in the mid 1970s (~6.4 million cases) and stabilizing trend to around 2 million cases in the 1990s. *Plasmodium falciparum* proportion has steadily risen to around 50% in the recent years and the remaining incidence is of *P. vivax* and a small proportion of *P. malariae*. Source: NVBDCP data



• Artemisinin



• Malaria Chloroquine
• Resistance




Fig. 9: Age and sex distribution of malaria mortality in India in 1998. The deaths are more in males than in females across all the ages while middle productive ages in general have much higher mortality than in children. N.S. = age not specified




EGG PHARMA

- 36% of the world's population is at risk for Malaria
- Burden of *P. Vivax* Malaria is est. – 71 to 80 million people!
- Asia & Western Pacific contributed 42 million in 2001.


Resistance to both artemisinin and Chloroquine is increasing rapidly.
In South East Asia, the risk of contracting Malaria is 80% !!

The spread of malaria parasites resistant to the drug artemisinin into India would pose a serious threat to the global control & eradication of malaria, researchers said.

“Arthemether + Coartem is not working due to resistance, and has side-effects + toxic chlorine”



•Artemisinin



•Coartem

- Current Chloroquine treatment
- Called Coartem by Novartis
- Already has Resistance in all of Africa and makes Cl_2 in body

Replacing the secondary acting substance with Berberine takes away the toxic chlorine of **Coartem** (Lumefantrine tablets) and gives the very effective Berberine that is already sold in hundred's of products in the USA under **goldenseal** branding

- Berberine is a well recognized anti-viral & -bacterial agent going back millennia in the **AYUSH & Ayurvedic National Institute**

Resistance to both artemisinin and Chloroquine is increasing rapidly.

By switching artemisinin therapy to ACT RX with Berberine and semi-synthetic Arthemether sublingual spray enables three-way cure

without Tolerance

“Thank You”

***ACTRX- The Dawning of New Hope
for Fighting
Dengue & Malaria***

“Insuring An Improved quality of life”



Energime Green Group Thailand, Ltd – Dr Wong
Dir: Jay Dubinsky, Chief Medical Dir: Dr. Krasnow
+34-653-736-622/www.lazerhead.net Licensed Manuf